Search this website. You can use fund codes to locate specific funds

Antimicrobial resistance and the challenge for pharmaceutical companies

A lack of research and development into new antibiotic classes compounds the serious threat that antimicrobial resistance poses to public health. In the fifth article in our pandemic series, Kimberley Lewis explores the role of pharmaceutical companies and how we engage on this key topic.

Fast reading

  • No major new class of antibiotics has been discovered since 1987
  • Pharmaceutical companies struggle to make a commercial case for investing in antibiotics
  • We engage with pharma companies on how their R&D strategies address this public health threat

The increasing prevalence of antimicrobial resistance (AMR) jeopardises the efficacy of existing life-saving antibiotics, as we explained in our previous article in this series. The problem is compounded by the lack of development of new antibiotic classes in the pharmaceutical sector. In this article, we will explore the reasons for this pipeline problem, as well as potential solutions.

The challenge

No major new class of antibiotics has been discovered since 1987 and too few antibacterial agents are in development to meet the challenge of multi-resistant bacteria. According to the World Health Organization (WHO), of the 50 new antibiotics in clinical development, few are considered innovative enough to add significant value to the current pool of antibiotics.

Given the discovery void since the late 1980s, the pharmaceutical industry needs to accelerate its R&D efforts to develop new antibiotic classes and keep pace with the evolution of multi-resistant bacteria. There will be a great human and financial cost if this does not occur. According to the WHO, there are few potential treatment options for those multi-resistant bacteria identified as posing the greatest threat to health. Without effective antimicrobials for prevention and treatment of infections, medical procedures such as organ transplantation, cancer chemotherapy, diabetes management and major surgery (for example, caesarean sections or hip replacements) become very high risk. Furthermore, AMR increases the cost of healthcare due to longer stays in hospital and the fact that more intensive care is required.

Currently, pharmaceutical companies are struggling to make a commercial case for investing in antibiotics. It is difficult to recoup the R&D costs due to the high cost of development, the low sales price of antibiotics compared with other drugs, and the fact that resistance development can happen quickly, impacting usability and long-term sales. Also, returns on investment will be limited because of restrictions in the use of the newly developed antibiotic to preserve efficacy. While pharmaceutical companies are traditionally paid based on the volume of the product sold, governments and other key stakeholders are trying to reduce antibiotic use.

Potential solutions

In the face of a growing AMR threat, we need to stimulate more research into new antibiotic classes. This will require more partnerships and cooperation among policymakers, academics and the pharmaceutical industry in order to address the scientific, regulatory and economic challenges. It should also involve commercial incentives, which would need to be beneficial for society and provide a reasonable return on investment for pharmaceutical companies. There is some positive momentum in these areas, for example:

  • As part of a Global Action Plan on Antimicrobial Resistance, the WHO and the Drugs for Neglected Diseases initiative jointly launched the Global Antibiotic Research and Development Partnership. This encourages R&D through public-private partnerships. By 2023, the goal is to develop and deliver up to four new treatments by improving existing antibiotics and accelerating the entry of new antibiotic drugs.
  • The United States has enacted a law to stimulate the development of new antibiotics. The law increases the commercial value of antibiotics that are intended for serious or life-threatening infections by extending the period for which the drugs can be sold without competition from generic drugs by five years. New drugs that could benefit from this law are now in the antibiotic pipeline. The UK government is testing a ‘subscription’ style model that pays pharmaceutical companies upfront for access to drugs based on their usefulness to the NHS.
  • In July 2020, more than 20 biopharmaceutical companies announced their participation in the industry-led AMR Action Fund, which will support the research of new antibiotics. It pledges to invest US$1bn with the aim of bringing two to four novel antibiotics to market by 2030. The initiative also commits to creating shared technical resources and enabling co-operation across supporters’ research efforts in order to streamline the development process and reduce the cost of the clinical development of new drugs.

Engagement

We know it is not enough to develop new antibiotics. Responsible and robust manufacturing, sales and use practices must also be in place to slow the development of AMR, which we address through our engagement with companies.

We engage with pharmaceutical companies on how their R&D strategies address this public health threat, whether responsible sales practices are in place, and how effluence at production sites is managed to ensure that antibiotics do not enter the environment. We ask companies to assess and acknowledge the risk of AMR to their business. We expect companies to support partnerships and advocacy campaigns that encourage public policy solutions. In the next article in this series, we will discuss our engagement on pharmaceutical companies’ responses to the current pandemic.

We appreciate that the development of new antibiotics will not alone counteract the challenges posed by AMR, as AMR is a natural and continuous selection process that occurs when antibiotics are used. Existing and new antibiotics will need to be used more sparingly through effective antibiotic stewardship. However, we need more innovation in this field, as well as in vaccine development and diagnostics. This will require a concerted, global effort to accelerate the pace of pharmaceutical R&D.

Related Insights

Climate change and human rights
Climate change is not only having a devastating impact on the environment, it is also a human rights issue.
NetEase case study
NetEase published its inaugural ESG report in June 2020, covering material ESG topics including data privacy and protection, and GDPR compliance. EOS is pleased with its commitment to improve shareholder communication and continues to engage with the company on the wider ESG agenda.
HEINEKEN case study
HEINEKEN has improved the standard and transparency of its business conduct policies, increasing investor confidence. EOS continues to engage with the company on its accountability to its key values of integrity and fairness and on other ESG issues.
Takeda Pharmaceutical case study
Takeda Pharmaceutical has significantly improved the transparency and accountability of its executive remuneration, aligning itself more closely to global peers. EOS has engaged it on this topic for the past 16 months to increase investor confidence in the company for the long term.
Federated Hermes calls on companies to halt and reverse biodiversity loss following UN Summit
EOS call on companies to halt and reverse the loss of biodiversity following yesterday’s UN Biodiversity Summit.
Burberry case study
Burberry has reaffirmed its commitment to find alternatives to incinerating surplus stock in the midst of the coronavirus pandemic and set a science-based carbon reduction target.

EOS Client Service and Business Development

Amy D’Eugenio,
Head of Client Service and Business Development, EOS